Literature DB >> 24024705

Randomised clinical trial: MRCP-first vs. ERCP-first approach in patients with suspected biliary obstruction due to bile duct stones.

M Bhat1, J Romagnuolo, E da Silveira, C Reinhold, E Valois, M Martel, J S Barkun, A N Barkun.   

Abstract

BACKGROUND: The preferred initial investigation with either magnetic resonance (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) in patients with suspected biliary obstruction remains controversial in many clinical settings. AIM: To assess the effectiveness of an initial MRCP vs. ERCP in the work-up of patients at moderate likelihood of a suspected biliary obstruction.
METHODS: Patients with an unconfirmed benign biliary obstruction, based on laboratory and ultrasound findings, were randomised to an ERCP-first or MRCP-first strategy, stratified by level of obstruction. The primary outcome was the occurrence of a disease or procedure-related bilio-pancreatic adverse events within the next 12 months. Secondary outcomes were the number of subsequent bilio-pancreatic procedures, duration of hospitalisation, days away from activities of daily living (ADL), quality of life (SF-36) and mortality.
RESULTS: We randomised 126 patients to ERCP-first and 131 to MRCP-first (age 54 ± 18 years, 62% female, 39% post-cholecystectomy). In follow-up, 18/126 (14.3%) ERCP-first and 25/131 (19.1%) MRCP-first patients experienced a procedure- or disease-related complication (P = 0.30) (disease-related in 13 and 18 patients, and procedure-related in 5 and 7 patients respectively). A cause of biliary obstruction was found in 39.7% vs. 49.6% of patients (P = 0.11). Sixty-six (50%) patients in the MRCP-first group ended up avoiding an ERCP in follow-up. ERCP-first and MRCP-first patients were away from usual activities for 3.4 ± 7.7 days and 2.0 ± 4.8 days respectively (P < 0.001).
CONCLUSION: A strategy of MRCP-first decreased the need for subsequent MRCPs, but not complications. Further study is required to define factors influencing the eventual use of MRCP vs. ERCP in appropriately selected patients (ClinicalTrial.gov: NCT01424657).
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24024705     DOI: 10.1111/apt.12481

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Diagnostic value of magnetic resonance cholangiopancreatography in choledocholithiasis.

Authors:  Wen Chen; Jing-Jia Mo; Li Lin; Chao-Qun Li; Jian-Feng Zhang
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

2.  Endoscopic Retrograde Cholangiopancreatography (ERCP) in Patients With Liver Cirrhosis: Analysis of Trends and Outcomes From the National Inpatient Sample Database.

Authors:  Shantanu Solanki; Asim Kichloo; Dushyant S Dahiya; Dhanshree Solanki; Jagmeet Singh; Farah Wani; Michael Albosta; Subash Ghimire; Khwaja F Haq; Hafiz M A Khan; Syed-Mohammed Jafri; Mohammad Arsalan Siddiqui; Tobias Zuchelli
Journal:  J Clin Gastroenterol       Date:  2021-06-09       Impact factor: 3.174

3.  Unusual Use of Gd-EOB-DTPA in MRCP in Order to Reveal the Source of Bile Leakage in a Patient with Neuroendocrine Tumor - Case Report.

Authors:  Rafał Mazur; Aleksander Pawluś; Kinga Szymańska; Mateusz Patyk; Anna Otlewska; Krzysztof Międzybrodzki; Dąbrówka Sokołowska-Dąbek; Eliza Kubicka; Urszula Zaleska-Dorobisz
Journal:  Pol J Radiol       Date:  2016-11-14

4.  Prevalence and characteristics of clinically significant retained common bile duct stones after laparoscopic cholecystectomy for symptomatic cholelithiasis.

Authors:  Doo-Ho Lee; Young Joon Ahn; Hae Won Lee; Jung Kee Chung; In Mok Jung
Journal:  Ann Surg Treat Res       Date:  2016-10-31       Impact factor: 1.859

5.  The future of ERCP.

Authors:  Richard A Kozarek
Journal:  Endosc Int Open       Date:  2017-04

6.  Overexpressed CD39 mitigates sepsis‑induced kidney epithelial cell injury via suppressing the activation of NLR family pyrin domain containing 3.

Authors:  Meixia Yang; Linxin Lu; Zhiqin Kang; Tianlong Ma; Yu Wang
Journal:  Int J Mol Med       Date:  2019-09-23       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.